CMS Conditions of Participation for Outpatient Infusion Centers

CoPs and Conditions for Coverage (CfCs) are the health and safety standards CMS requires health care organizations to meet in order to begin and continue participating in Medicare and Medicaid. CMS defines CoPs and CfCs as the foundation for improving quality and protecting beneficiary health and safety, and they apply across a defined list of provider types including hospitals, ambulatory surgical centers, home health agencies, and clinics providing outpatient services.

Infusion care does not happen in one kind of building, and that matters for anyone trying to figure out which rules apply. A patient might get an infusion in a hospital outpatient department, at a freestanding ambulatory infusion center, in a physician's office suite, or at home through a home infusion supplier. The CoP framework that applies differs by setting, so a center's compliance obligations are partly determined by how it is licensed and enrolled.

Accreditation offers one path to meeting these standards without CMS inspecting every site directly. Accreditation by a CMS-approved accrediting organization, a process called "deeming," can satisfy CoP requirements. Home infusion therapy suppliers deal with this directly: the Accreditation Commission for Health Care is one of several CMS-approved accrediting bodies, alongside The Joint Commission, NABP, and URAC, that holds this deemed status. Accreditation is not permanent. ACHC accreditation runs for a 36-month cycle, and renewal preparation needs to start at least nine months before it expires.

None of this answers the question of how a center gets paid. Clearing the CoP bar confirms a center is allowed to operate and bill in the Medicare program. It says nothing about the rate a given service earns or which payment system applies to it, and that gap is exactly where the next layer of the regulatory picture begins.

Medicare Participation Requirements for Infusion Suppliers

Passing CoP inspection or holding accreditation gets a center in the door. Actually collecting Medicare payment requires a second, separate step: enrolling correctly as the right kind of provider or supplier. Enrollment type is what determines which payment system governs a given claim, so a center can be fully compliant on the safety side and still bill incorrectly if its enrollment does not match the service it is providing.

Home infusion therapy suppliers show this chain clearly. Section 1861(s)(2)(iii) of the Social Security Act requires the Secretary to establish the conditions that home infusion therapy suppliers must meet to participate in Medicare, conditions considered necessary to ensure the health and safety of patients. To qualify, a home infusion therapy supplier needs two things at once: accreditation from a Medicare-approved accrediting organization, and enrollment in Medicare as a Part B supplier. Neither one substitutes for the other.

Once a supplier is enrolled, the billing mechanics get specific fast. CMS Transmittal 10547, effective January 1, 2021, laid out the claims processing rules for home infusion therapy billing under the 21st Century Cures Act, covering professional services like nursing, plan of care documentation, which drugs qualify, and how to distinguish an initial visit from a subsequent one. Every one of those elements has to show up in the documentation before a claim is payable. And the rates behind those claims move independently of the underlying conditions. CMS published updated CY 2026 Home Infusion Therapy national rates on December 5, 2025, including geographic adjustment factors and locality-adjusted rates for initial and subsequent visits. The conditions of participation do not change every year. The payment rates behind them do.

The same logic carries over into outpatient infusion more broadly, where the setting a center operates in decides the payment system that applies to it. Hospital-based outpatient services get paid under OPPS. Physician offices get paid under the Medicare Physician Fee Schedule. Home infusion therapy suppliers get paid under their own dedicated payment system. A center's enrollment decision determines which of these payment systems governs its claims, and getting that wrong upstream creates problems no amount of clean coding can fix downstream.

The supervision standard that changed for freestanding centers on January 1, 2026

Freestanding infusion centers and physician office suites have long operated under a direct supervision requirement: the supervising physician had to be immediately available, physically, on-site. That standard changed in a meaningful way at the start of 2026.

As of January 1, 2026, CMS permanently allows direct supervision to be satisfied through real-time audio and video technology. A physician can now meet the "immediately available" standard through live, two-way video instead of standing in the building. This is a change in how the requirement gets met. The physician still has to be available in real time, capable of stepping in immediately if a patient needs attention. What changed is the acceptable form that availability takes.

The bar for what counts as compliant technology is specific, and it excludes a common workaround. Audio-only connections do not satisfy the standard. The rule calls for real-time, two-way audio-video, and that requirement is not flexible. A phone call from a supervising physician, no matter how quickly answered, does not meet it.

For centers that operate in areas with thin physician coverage, or where one supervising physician splits time across multiple sites, this single change reshapes what a compliant staffing model can look like. A physician can now supervise infusion administration at a location without being physically present there, provided the video connection is live and two-way at the moment supervision is needed. Centers that want to rely on this option should be maintaining records that show the video connection was in fact real-time and two-way during the relevant administration window, since that is the exact detail the standard hinges on. The operational door has opened wider. It has not been removed from its frame.

Site-Neutral Payment and Outpatient Infusion Centers' Financial Position

Of everything that changed for outpatient infusion centers in 2026, the coding updates are not what reshapes the financial map. The structural expansion of site-neutral payment does that, and it cuts directly at the rate advantage hospital-based outpatient departments have held over independent infusion settings for drug administration services, including chemotherapy infusion.

The mechanism goes back further than 2026. Since the Bipartisan Budget Act of 2015, CMS has paid new or relocated off-campus provider-based departments at a site-neutral rate, one pegged to the Medicare Physician Fee Schedule rather than the higher OPPS rate. That site-neutral rate sits substantially below what OPPS would otherwise pay for the same service. The CY 2026 final rule, released November 21, 2025, extended that site-neutral policy specifically to drug administration services. That is the detail independent infusion centers have been waiting on: a hospital outpatient department administering chemotherapy or biologics under these newly covered categories no longer collects the old OPPS premium for doing so.

Why should an independent infusion center care what a hospital gets paid? IPA's comments explicitly framed the payment disparity: hospitals currently benefit from higher payments and significant drug acquisition advantages for administering identical Part B drugs compared to independent, non-hospital physician offices and infusion clinics. Narrowing the payment gap does not just move money around inside the hospital system. It changes the competitive position of every independent center that has been operating in that system's shadow.

None of this should be read as a settled win for independent infusion providers. IPA's own comments framed adequate funding for non-hospital infusion providers as an open question, not a solved one, arguing that long-term site-of-service reform has to leave these providers with both the incentive and the capacity to take on patients who might otherwise be turned away from hospitals. Site-neutral payment reform is being pitched as a patient access issue as much as a cost-control measure, and that framing only holds if independent centers are funded well enough to absorb the patients a rebalanced system sends their way.

The reform also is not finished. The CY 2026 OPPS proposed rule, CMS-1834-P, posted July 17, 2025 with a comment period that closed September 15, 2025, included a request for information on adjusting OPPS payment for services predominantly performed in ASC or physician office settings. That signals site-of-service payment reform will keep evolving past the 2026 rule itself. Centers watching this space should expect further changes.

2026 OPPS Coding and Documentation Changes for Infusion Billing Operations

Site-neutral payment resets the rate. Whether a center actually collects that rate depends on a separate set of coding and documentation rules that got more demanding in 2026. A center that has fully internalized the new payment structure but has not adjusted its documentation practices will simply fail to collect what it is now owed.

The 2026 changes sharpen several distinctions that used to be looser. Initial, subsequent, and concurrent infusion codes now carry clearer boundaries, with revised time thresholds attached to each category. CMS's 2026 infusion billing changes include revised HCPCS codes for selected oncology and biologic drugs and stronger linkages between the type of drug and the proper administration code used to bill for it. None of this is a one-time update a billing team can absorb once and move past. It requires ongoing attention every time a code set refreshes.

Time documentation carries more weight under the new rules than it used to. Start and stop times for each infusion need to be recorded accurately, multi-drug regimens need consistent sequencing, any interruption or switch between infusion types needs to be captured, and the time documentation needs to tie directly to each billed unit. A missing stop time or an unrecorded interruption leaves a unit unable to support its own billing.

Wastage reporting tightened as well. Modifiers are now mandatory for all eligible drugs, and payers are validating billed units more closely against the vials actually opened, with more frequent checks comparing acquisition cost, units used, and quantities billed. Drugs with a known history of wastage risk now draw expanded audit attention.

HCPCS Level II changes land directly on J-code billing. New codes were added in 2026 and others were removed. A center has to confirm the correct HCPCS code, dosing unit, and billing modifier every time the quarterly pricing file updates a product. Skipping that check on even one drug can push a clean-looking claim straight into a denial.

Unit errors on J-codes remain the single most damaging coding failure in this environment. Medicare and private payers both run automated unit-matching tests, and a material share of outpatient J-code denials trace back to erroneous billing units. Mismatching an intravenous J-code with a subcutaneous injection CPT code creates an immediate billing vulnerability.

CMS continues to refine its processes for collecting, auditing, and adjusting ASP data, and discrepancies in billing will result in delayed claims or retrospective adjustments. Biosimilars and newly launched infusion drugs need particular attention each quarter, since their pricing data is the most likely to shift. Coding accuracy in 2026 is a standing operational obligation with no end date. It is a standing operational obligation that resets every quarter.

Prior Authorization Failures as the First Revenue Loss Event in 2026

By the time a claim reaches coding review, the biggest revenue risk may already have been decided weeks earlier. Prior authorization is where infusion revenue is first won or lost, because a lapse or mismatch at that stage makes every downstream coding decision moot.

Specialty infusion therapies and biologics have drawn increasingly aggressive prior authorization requirements, and 2026 pushes that trend further: payers are expanding reauthorization demands, and reauthorizations tied to ongoing infusion treatment have become a growing, distinct source of denials. This is a process and timing challenge more than a technology gap. Centers that treat prior authorization as a single event, cleared once before treatment starts, are working from the wrong model. Reauthorization is a recurring checkpoint that has to be tracked across the entire treatment cycle.

Approval timelines make that tracking urgent. Documented J-code prior authorization approval times across 2024 and 2025 ranged from several days to more than two weeks for standard cases, and some Medicare Advantage cases ran well beyond that window. A center that is not tracking authorization status in real time is exposed to scheduling conflicts and drug-ordering risk on every case where approval takes longer than expected.

Step therapy adds a separate, state-specific barrier. Starting January 1, 2026, Connecticut law prohibits insurers from requiring step therapy at all for drugs treating multiple sclerosis or rheumatoid arthritis. New York law takes a different approach, limiting step therapy generally to no more than 30 days regardless of condition, after which a provider can deem the step therapy drug ineffective and move straight to the originally prescribed treatment. These protections only help a center that knows exactly which state law applies to which payer and which therapy. A center operating across state lines cannot assume the same step therapy rules apply everywhere.

The real operational failure point sits in the middle of the treatment cycle, not at the start. Most infusion medications require renewed authorization tied to dosing schedules or documented treatment response, and a center that handles the initial authorization well but has no system for tracking reauthorizations will watch denials build up mid-cycle on its highest-dollar biologics. The fix is structural: authorization lifecycle management has to begin before the treatment cycle starts, with reauthorization deadlines tracked from day one, rather than waiting for a lapse to surface as a denial.

Buy-and-Bill Exposure and Denial Prevention as a Cash-Flow Matter

Buy-and-bill billing creates a financial exposure that most other specialties simply do not carry. The center purchases the drug before it ever submits a claim, and if that claim comes back denied, underpaid, or coded with the wrong units, the center is left holding the acquisition cost with nothing to offset it. At the price points common to specialty biologics, a single denied claim is an immediate cash-flow event. It is an immediate cash-flow event.

The coding changes covered earlier make this exposure sharper in 2026, not softer. A center that mismatches J-code units, documents wastage incorrectly, or applies an outdated quarterly ASP price does not just get paid a little less on that claim. It gets a denial or a retrospective adjustment on a claim that may carry tens of thousands of dollars in drug cost already spent. The dollar amount at risk on a single infusion claim separates this specialty's billing risk from most others.

Compliance obligations stack on top of each other rather than sitting in isolation. A buy-and-bill claim has to clear drug pricing rules under federal pharmaceutical discount programs, Medicare Part B drug billing requirements, clinical trial billing compliance under the Medicare Clinical Trial Policy where applicable, and state-level step therapy exemption laws, all at once. Falling out of compliance with any single one of these frameworks can trigger a denial even when the clinical care was appropriate and the primary billing code was correct. Accuracy on the main billing code is necessary but it is not sufficient protection on its own.

Commercial payers add another layer that Medicare rate knowledge does not cover. Commercial contracts run on proprietary fee schedules that diverge from Medicare's ASP-based rates: some set fixed percentages of ASP, some use AWP baselines, and some carve out contract-specific exceptions. Knowing the Medicare rate for a drug does not tell a center what a specific commercial payer owes on that same drug. Each payer contract has to be loaded and enforced at the line-item level, or underpayment slips through undetected until it becomes a permanent write-off. In a buy-and-bill model, that kind of undetected underpayment is drug cost the center already paid for and will never recover.

Underpayments in infusion remittances and why they compound silently under the 2026 payment rules

Underpayment behaves differently from denial, and that difference is what makes it dangerous. A denial announces itself: the claim comes back rejected, and someone on the billing team has to respond. An underpayment often does not announce anything. The remittance shows a payment, the claim appears closed, and the shortfall between what the contract specifies and what actually arrived sits quietly on the books unless someone is checking for it line by line.

That quiet failure mode shows why line-item contract enforcement matters as much as denial management. Commercial payers running fixed ASP percentages, AWP baselines, or contract-specific carve-outs will not flag their own underpayments. A center has to load every payer contract and check every remittance against it, drug by drug, unit by unit, to catch the gap before it becomes permanent. Once a claim ages past the window for appeal or resubmission, an underpayment stops being a correctable error. It becomes a write-off, and the drug cost behind it is gone for good.

The 2026 coding and ASP changes make underpayments easier to miss, not harder to cause. Quarterly ASP pricing updates shift the benchmark a center should be comparing its remittances against. A center working from a pricing file that is even one quarter out of date may not notice that a payment lines up with an old rate rather than the current one, because the claim still gets paid, just at the wrong number. The same is true of the revised HCPCS codes and dosing units introduced in 2026: a remittance that reflects the old code or the old unit conversion can look like a normal payment while actually falling short of what the current rate schedule specifies.

Every underpayment that goes unchecked adds to a total that appears not as a single alarming event but as a slow, steady gap between what a center billed and what it should have collected across hundreds of infusion claims a month. In a buy-and-bill model, where every underpaid claim represents drug cost the center already spent, that gap is margin quietly leaving the practice. It is margin quietly leaving the practice, one remittance at a time, under payment rules that reward the centers watching closely enough to catch it, a problem that platforms built specifically for infusion revenue cycle management, such as Ruby RCM, a billing and AR platform purpose built for infusion centers that combines software with hands-on operators to enforce contracts at the line-item level, are designed to surface before the appeal window closes.